Thank you.
We list Mefloquine as a medication because it's very effective, and the U.S. continues to use it, contrary to misperceptions misreported in the media. It remains recommended by the Public Health Agency of Canada's committee on advice on tropical medicine and travel, the World Health Organization, and the U.S. Centers for Disease Control. The big advantage is that it's just once-a-week dosing instead of daily dosing. A life-threatening illness like malaria, as a result of missing one dose of one of the alternatives, could cost your life. It's not obligatory; it's elective.
We usually offer a choice usually of three drugs: Doxycycline, Malarone, and Mefloquine. Most people will now take Malarone, but in some cases, because of various contraindications—intolerance of Malarone or Doxycycline—they will decide to take Mefloquine, or simply because of the convenience of having to use it only once a week. Many countries among our allies continue to use Mefloquine exclusively because of its effectiveness against malaria.
In the U.S. and Australia, all they've done is take it away from being the primary drug of choice as an antimalarial to making it one of the second-line treatments. The reason the Americans did that is not because of concerns about mental health or its psychological impacts, but because of the logistical burden of the time it takes them, with the mass number of troops they deploy: to screen them for the potential contraindications was just too much of a burden. For that reason, and that reason alone, they made it a second-line drug.
There has also been a suggestion of a causal link between Mefloquine and post-traumatic stress disorder by one paper in the U.S., but the author of the paper indicated that it was likely an idiosyncratic, unusual, extreme reaction in only one specific case.
We screen people for any of the contraindications that make them more susceptible to potentially having an adverse reaction to Mefloquine should they themselves, individually, choose to take Mefloquine.